Holen Sie sich die Stockscreener-App
210.73
0.83%
-1.77
Vorhandelsmarkt:
210.20
-0.53
-0.25%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$212.50
Offen:
$210.5
24-Stunden-Volumen:
694.49K
Relative Volume:
0.64
Marktkapitalisierung:
$31.14B
Einnahmen:
$9.60B
Nettoeinkommen (Verlust:
$1.37B
KGV:
22.61
EPS:
9.3182
Netto-Cashflow:
$2.32B
1W Leistung:
-5.36%
1M Leistung:
+1.34%
6M Leistung:
+11.95%
1J Leistung:
+46.75%
1-Tages-Spanne:
$209.00
$213.48
1-Wochen-Bereich:
$209.00
$225.80
52-Wochen-Spanne:
$135.39
$225.80
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
210.73 | 31.40B | 9.60B | 1.37B | 2.32B | 9.3182 |
LLY
Lilly Eli Co
|
1,124.21 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
267.08 | 648.55B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
250.91 | 439.62B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
147.53 | 366.28B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
137.48 | 261.73B | 54.66B | 13.58B | 16.05B | 7.0171 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-22 | Hochstufung | UBS | Neutral → Buy |
| 2026-04-20 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-04-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-09 | Bestätigt | H.C. Wainwright | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Can Biogen (NASDAQ:BIIB) Stay Resilient As Inflation Rises? - Kalkine Media
Biogen at Wells Fargo healthcare conference: growth bets widen By Investing.com - Investing.com Canada
Biogen Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
Learn Why The Bull Case For Biogen Stock Could Change Following Canada Reimbursement Backing - simplywall.st
Monoclonal Antibodies Market to Grow at 11.01% CAGR, Reaching USD 791.28 Billion by 2035 – SNS Insider - GlobeNewswire Inc.
Biogen Inc (BIIB) Shares Fall 3.8% -- What GF Score of 73 Tells Investors - GuruFocus
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers - Reuters
Biogen Must Face Pharmacies' MS Drug Monopoly Suit - law360.com
(BIIB) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Biogen stock heads into the open without fresh price data - ad-hoc-news.de
Biogen Inc. (BIIB) Investor Outlook: Navigating Growth in the Healthcare Sector with a Potential 7.26% Upside - DirectorsTalk Interviews
Biogen Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Biogen Inc. stock holds near 12 month high on steady Q1 2026 growth - ad-hoc-news.de
BIIB Stock Price Prediction 2026-2027 | Biogen Forecast - 24/7 Wall St.
Biogen Inc. (BIIB) Peer Comparison – Compare with Others - Value Research
Eisai, Biogen Secure China's Nod for Self-Injection Version of Leqembi - marketscreener.com
Biogen (BIIB), Why Is Its Latest Update Drawing Fresh Attention? - simplywall.st
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) - Biogen
Up to 20% of children with Dravet syndrome die before adulthood. A long-term study of an experimental drug showed fewer severe seizures. - Stock Titan
Biogen (BIIB) awards 7,405 stock units to its top lawyer - Stock Titan
Biogen Is Repositioning Its Portfolio To Partly Offset Ongoing Revenue Declines - Morningstar
Piper Sandler raises Biogen stock price target on pipeline outlook - Investing.com
Eisai, Biogen Win China Approval for Leqembi Self-Injection - International Business Times
Price cut becomes the price of coverage for Alzheimer's drug lecanemab - Benefits and Pensions Monitor
Biogen (BIIB) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $BIIB - MarketBeat
Biogen Inc. (BIIB) Key Financial Ratios – Valuation, Profitability & More - Value Research
Eisai and Biogen Announce China Approval of LEQEMBI SC-AI for Initiation Treatment of Early Alzheimer’s Disease - Quiver Quantitative
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China - Biogen
Biogen (BIIB) Stock Could Be 48% Below Fair Value On New Dravet Data - Yahoo Finance
How Biogen’s (BIIB) At-Home LEQEMBI Injections Could Reframe the Alzheimer’s Treatment Investment Story - simplywall.st
Biogen Inc (BIIB) Shares Surge 3.1% -- What GF Score of 73 Tells Investors - GuruFocus
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen gains as pipeline updates and fresh Street target hikes buoy sentiment - Quiver Quantitative
Biogen stock hits 52-week high at 222.86 USD By Investing.com - Investing.com Canada
Biogen stock hits 52-week high at 222.86 USD - Investing.com
A potential seizure treatment will be presented Sept. 9 by Stoke Therapeutics - Stock Titan
Biogen’s (BIIB) Immunology Bet Meets A Pricier Balance Sheet - Yahoo Finance
BIIB | Biogen Inc. Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
Stoke, Biogen present 4-year zorevunersen data for Dravet syndrome - Investing.com
Stoke, Biogen Present 4-Year Dravet Syndrome Data at EEC | BIIB Stock News - Stock Titan
Eisai and Biogen Announce Canada’s Drug Agency Final Recommendation Supporting Public Reimbursement of LEQEMBI for Eligible Early Alzheimer’s Disease Patients - Quiver Quantitative
Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease - Biogen
Final CDA-AMC Recommendation Brings Canadians with Early-Stage Alzheimer's Disease One Step Closer to Accessing LEQEMBI® (lecanemab) - PR Newswire Canada
Price to book forward of Biogen Inc. – NASDAQ:BIIB - TradingView
Biogen Inc. (BIIB) Stock Report: Analyst Ratings Signal Potential Upside Of Over 8% - DirectorsTalk Interviews
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report? - Yahoo Finance
Will Biogen (BIIB) Make Early Alzheimer’s Treatment Easier At Home? - simplywall.st
RBC Capital raises Biogen stock price target on lupus drug potential - Investing.com
Eisai and Biogen Launch LEQEMBI IQLIK Subcutaneous Injection for Early Alzheimer’s Disease in the U.S. - Quiver Quantitative
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):